Wedbush Reaffirms “Outperform” Rating for AnaptysBio (NASDAQ:ANAB)

Wedbush reiterated their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note issued to investors on Monday morning,RTT News reports. The brokerage currently has a $40.00 price objective on the biotechnology company’s stock. Wedbush also issued estimates for AnaptysBio’s Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($4.13) EPS, FY2028 earnings at ($4.77) EPS and FY2029 earnings at ($4.04) EPS.

Several other brokerages also recently issued reports on ANAB. JPMorgan Chase & Co. reduced their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. UBS Group boosted their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wells Fargo & Company lowered their price target on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. HC Wainwright lowered AnaptysBio from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $52.00 to $19.00 in a report on Wednesday, December 11th. Finally, Guggenheim lowered their target price on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.08.

AnaptysBio Stock Down 2.7 %

Shares of NASDAQ ANAB opened at $16.06 on Monday. The stock’s fifty day simple moving average is $17.05 and its 200 day simple moving average is $26.77. The stock has a market capitalization of $488.71 million and a price-to-earnings ratio of -2.64. AnaptysBio has a 52-week low of $12.51 and a 52-week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. The company had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current year.

Insider Transactions at AnaptysBio

In related news, Director Ecor1 Capital, Llc bought 6,646 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was acquired at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the transaction, the director now directly owns 7,880,094 shares of the company’s stock, valued at $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 33.70% of the stock is owned by insiders.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently made changes to their positions in ANAB. China Universal Asset Management Co. Ltd. grew its stake in shares of AnaptysBio by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 644 shares during the last quarter. Algert Global LLC lifted its holdings in AnaptysBio by 11.8% during the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after buying an additional 1,078 shares in the last quarter. Rhumbline Advisers boosted its position in AnaptysBio by 3.8% in the 4th quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock valued at $398,000 after buying an additional 1,111 shares during the last quarter. nVerses Capital LLC increased its stake in shares of AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares during the period. Finally, Values First Advisors Inc. bought a new stake in shares of AnaptysBio during the third quarter worth $49,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.